NOW APPROVED
DUPIXENT is indicated for the treatment of adult and pediatric patients aged 12 years
and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).The mechanism of dupilumab action has not been definitively established.
DUPIXENT is not an immunosuppressant1
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Learn how we can help6+ MONTHS OF AGE
Uncontrolled moderate-to-severe
6+ YEARS OF AGE
Eosinophilic phenotype or
18+ YEARS OF AGE
Inadequately controlled
12+ YEARS OF AGE
Weighing at least 40 kg
CRSwNP, chronic rhinosinusitis with nasal polyposis; OCS, oral corticosteroids.
References: